Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

ClinicalTrials.gov ID: NCT06257693

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06257693. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study to Establish the Feasibility of Enolen (tm) for the Local Delivery of Enzalutamide in Patients With Prostate Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.

Study identification

NCT ID: NCT06257693
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Alessa Therapeutics Inc.; Industry
Enrollment: 45 participants

Conditions and interventions

Conditions

Prostate Adenocarcinoma

Interventions

enzalutamide Drug

Drug

Eligibility (public fields only)

Age range: 21 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 21, 2024 (Actual)
Primary completion: Dec 30, 2028 (Estimated)
Completion: Dec 30, 2028 (Estimated)
Last update posted: Aug 11, 2026

2024 – 2028

United States locations

U.S. sites: 10
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
Urology Associates of Central California	Fresno	California	93720	Recruiting
University of California San Francisco Helen Diller Family Comprehensive Cancer Center	San Francisco	California	94158	Recruiting
Northwestern University	Chicago	Illinois	60611	Recruiting
Mary Bird Cancer Center	Metairie	Louisiana	70002	Recruiting
Johns Hopkins University School of Medicine	Baltimore	Maryland	21287	Recruiting
National Institutes of Health Clinical Center	Bethesda	Maryland	20892	Recruiting
VA Portland Health Care System	Portland	Oregon	97239	Recruiting
Atlantic Urology Specialists	Myrtle Beach	South Carolina	29572	Recruiting
Virginia Commonwealth University	Richmond	Virginia	23298	Recruiting
Aurora Urology	Milwaukee	Wisconsin	53215	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06257693, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 11, 2026 · Synced Nov 14, 2026